A natural expansion into NASH

Non-alcoholic steatohepatitis (NASH) occurs when fat accumulates in the liver due to causes other than excessive alcohol consumption. It is a progressive liver disease characterised by inflammation and fibrosis, and has strong links to diabetes, obesity and cardiovascular diseases1. By 2030, the number of NASH patients is expected to increase by 60% and the number of liver deaths related to NASH by 178%2. Currently, the majority of people who have NASH remain undiagnosed3 due to the invasive nature of diagnostic procedures and there are no approved pharmacological treatments for the disease. Novo Nordisk is working on solutions to both of these challenges.


“I’m excited about our pipeline! I believe we will bring effective medicines with high safety to market in the years to come – medicines that may change the lives of people with NASH.”

Martin Holst Lange
Senior Vice President
Global Development
LinkedIn profile

martin holst

NASH 80 Percent

More than 80% of people with NASH are also living with obesity3

NASH 40 Percent

More than 40% of people with NASH have diabetes3

NASH 5-6 Percent

5–6% people are estimated to be affected by NASH3

partnering opportunities

New opportunities in NASH care

We are always ready to build alliances to advance science and address unmet medical needs. Within NASH, we are looking for partners with expertise in novel modalities that address fibrosis and inflammation. To learn more about how we can work together, please visit our partnering pages.


Explore partnering possibilities

A painful diagnosis

Today, the diagnosis of NASH requires an invasive and often painful liver biopsy, and diagnosis rates are consequently low. To facilitate diagnosis and overcome treatment barriers, Novo Nordisk participates in international forums such as LITMUS, which support the identification of alternative, non-invasive means for diagnosing NASH as well as for monitoring progression or regression of the disease.?



Nimble and Litmus forum


Research hub in M?l?v (DK)

We are mobilising our expertise in metabolism and protein technology to discover and develop treatments for NASH. To support our aims, the cardiovascular and liver diseases research departments at our world-class research center in M?l?v, Denmark, are expanding their teams of drug researchers. Visit our careers page to learn more.


View R&D Jobs


Guided by the people who know best

At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.

Explore DEEP



Follow our progress

Explore our scientists’ work on new NASH treatments.

Recent publications

publications thumbnail

To contribute to the scientific community in our areas of expertise, we take pride in publishing our scientists’ new findings. Visit the library to review some of their recent work.


Explore our publications



A network that changes lives

Clinical trials thumbnail

Novo Nordisk conducts clinical trials in over 50 countries worldwide, and we have a high rate of retention among our trial participants.

Our clinical trials